NCT05419401 - A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

July 12, 2022

Study Completion Date

July 12, 2022

Conditions

Healthy Volunteer

Interventions

DRUG

Capivasertib film-coated tablet, 200 mg

400mg dose, oral, fasted

DRUG

[14C]AZD5363 (Capivasertib)

"Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted"

Trial Locations (1)

Research Site, Ruddington